Pricing Log in Create free account

Akebia Therapeutics, Inc. (AKBA) vs Organogenesis (ORGO)

Akebia Therapeutics, Inc. and Organogenesis are both Drug Manufacturers Specialty & Generic companies. Akebia Therapeutics, Inc. and Organogenesis are of similar size ($117.9M and $108.1M). Akebia Therapeutics, Inc. grew revenue faster over the last twelve months: −12.4% against −24.3%. Akebia Therapeutics, Inc. has the higher net margin (−22.6% vs −43.5%) and the higher return on invested capital (0.00% vs −52.2%). Across the 20 metrics below, Akebia Therapeutics, Inc. leads on 12 and Organogenesis on 8.

Valuation

Metric AKBA ORGO Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S 0.60 0.30 2.08
P/B 5.84 0.89 1.79
Price to free cash flow 8.59 30.18 16.29
EV/EBITDA n/m n/m 12.22
EV/Sales 0.05 0.27 2.87
Earnings yield (37.21%) (145.78%) (15.94%)
Free cash flow yield 11.64% 3.31% 0.00%

Profitability

Metric AKBA ORGO Drug Manufacturers Specialty & Generic median
Gross margin 78.90% 65.56% 53.51%
Operating margin (15.74%) (24.45%) 0.00%
Net margin (22.60%) (43.50%) (2.45%)
Free cash flow margin 7.03% 1.01% 0.00%
Return on equity (143.83%) (81.71%) (0.80%)
Return on assets (12.62%) (34.86%) (1.67%)
Return on invested capital 0.00% (52.15%) 0.00%

Growth

Metric AKBA ORGO Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (12.38%) (24.33%) 5.22%
EPS growth (last fiscal year) 93.94% 1,600.00% 42.91%
Revenue growth, 5-year CAGR (4.33%) 10.77% 7.24%
Net income growth, 5-year CAGR 0.00% 3.04% 0.00%

Health

Metric AKBA ORGO Drug Manufacturers Specialty & Generic median
Debt to equity 2.47 0.09 0.04
Current ratio 1.36 3.32 2.41
Net debt to EBITDA (5.51) (1.14) 1.01

Dividend

Metric AKBA ORGO Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric AKBA ORGO Drug Manufacturers Specialty & Generic median
Market cap 117.91m 108.08m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack